Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

PARLODEL

BROMOCRIPTINE MESYLATE

Standard Dose
EQ 5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PARLODEL is listed in Drugs@FDA under application 017962 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BROMOCRIPTINE MESYLATE Form and strength CAPSULE;ORAL - EQ 5MG BASE Sponsor ESJAY PHARMA Submission history Latest submission status date: 2021-07-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview PARLODEL is listed in Drugs@FDA under application 017962 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BROMOCRIPTINE MESYLATE Form and strength CAPSULE;ORAL - EQ 5MG BASE Sponsor ESJAY PHARMA Submission history Latest submission status date: 2021-07-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.